Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme.
Reads0
Chats0
TLDR
The DELIVER 2 study as mentioned in this paper showed that Gla-300 provided similar antihyperglycaemic effectiveness and a lower risk of hypoglycaemia compared with the first-generation BI analogue insulin glargine 100 U/mL (Gla-100) in people with Type 2 diabetes.Abstract:
Evidence from randomized controlled trials (RCTs) has shown that second-generation basal insulin (BI) analogues, insulin glargine 300 U/mL (Gla-300) and insulin degludec (IDeg), provide similar glycaemic control, with a lower risk of hypoglycaemia compared with the first-generation BI analogue insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes (T2D). However, the highly selected participants and frequent follow-up of RCTs may not be truly representative of real-life clinical practice. It is important to assess the safety and effectiveness of these second-generation BI analogues in real-life clinical practice settings. The DELIVER programme utilized electronic healthcare records from the United States to compare clinical outcomes in people with T2D who received either Gla-300 or other BI analogues in real-world clinical practice. This review provides a concise overview of the results of the DELIVER studies. Overall, Gla-300 provided similar antihyperglycaemic effectiveness and a lower risk of hypoglycaemia versus the first-generation BI analogues Gla-100 and insulin detemir in people with T2D who had switched BIs. In those who were insulin-naive, initiation with Gla-300 versus Gla-100 was associated with significantly better antihyperglycaemic effectiveness and similar or lower hypoglycaemic risk. Both glycaemic control and hypoglycaemia risk were also shown to be similar with Gla-300 and IDeg, in people who had switched BIs and in those who were insulin-naive. In addition, the DELIVER 2 study reported that people with T2D who switched to Gla-300 had reduced healthcare resource utilization, with an overall saving of US$1439 per person per year compared with those who switched to another BI analogue. Overall, the real-world DELIVER programme showed that the glycaemic control with a low risk of hypoglycaemia observed with Gla-300 in RCTs was also seen in standard clinical practice.read more
Citations
More filters
Journal ArticleDOI
iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study
Rory J. McCrimmon,Alice Y Y Cheng,Gagik R Galstyan,Khier Djaballah,Xuan Li,Mathieu Coudert,Juan P. Frias +6 more
TL;DR: In real-world clinical practice, glycaemic outcomes 6 months after treatment advancement from BI are similar for people with T2D using iGlarLixi versus BI + RAI, with iGlarycaemia leading to less weight gain.
References
More filters
Journal ArticleDOI
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Tadej Battelino,Thomas Danne,Richard M. Bergenstal,Stephanie A. Amiel,Roy W. Beck,Torben Biester,Emanuele Bosi,Bruce A. Buckingham,William T. Cefalu,Kelly L. Close,Claudio Cobelli,Eyal Dassau,J. Hans DeVries,Kim C. Donaghue,Klemen Dovc,Francis J. Doyle,Satish K. Garg,George Grunberger,Simon Heller,Lutz Heinemann,Irl B. Hirsch,Roman Hovorka,Weiping Jia,Olga Kordonouri,Boris Kovatchev,Aaron J. Kowalski,Lori M. Laffel,Brian J. Levine,Alexander Mayorov,Chantal Mathieu,Helen R. Murphy,Revital Nimri,Kirsten Nørgaard,Christopher G. Parkin,Eric Renard,David Rodbard,Banshi Saboo,Desmond A. Schatz,Keaton C. Stoner,Tatsuiko Urakami,Stuart A. Weinzimer,Moshe Phillip,Moshe Phillip +42 more
TL;DR: This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.
Journal ArticleDOI
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview
TL;DR: DCCT/EDIC has demonstrated the effectiveness of intensive therapy in reducing the long-term complications of T1DM and improving the prospects for a healthy life span and the durability of the DCCT effects on the more-advanced stages of diabetes complications including cardiovascular disease.
Journal ArticleDOI
Real-World Evidence — What Is It and What Can It Tell Us?
Rachel E. Sherman,Steven A. Anderson,Gerald J. Dal Pan,Gerry W. Gray,Thomas G. Gross,Nina L. Hunter,Lisa M. LaVange,Danica Marinac-Dabic,Peter W. Marks,Melissa A. Robb,Jeffrey Shuren,Robert Temple,Janet Woodcock,Lilly Q. Yue,Robert M. Califf +14 more
TL;DR: The FDA is developing guidance on the use of “real-world evidence” — health care information from atypical sources, including electronic health records, billing databases, and product and disease registries — to assess the safety and effectiveness of drugs and devices.
Journal ArticleDOI
New Insulin Glargine 300 Units·mL−1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mL−1
TL;DR: Gla-300 provides more even steady-state PK and PD profiles and a longer duration of action than Gla-100, extending blood glucose control well beyond 24 h, as supported by the later time curves.
Journal ArticleDOI
Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials
Robert E. Ratner,Stephen C. L. Gough,Chantal Mathieu,S. Del Prato,B Bode,Henriette Mersebach,Lars Endahl,Bernard Zinman +7 more
TL;DR: This pre‐planned meta‐analysis aimed to demonstrate the superiority of IDeg over insulin glargine (IGlar) in terms of fewer hypoglycaemic episodes at equivalent HbA1c in type 2 and type 1 diabetes mellitus (T2DM/T1DM).